Print

Bristol-Myers Squibb Company (BMY) Release: New Data on the Use of Investigational Agent Belatacept in Kidney Transplant Recipients to Be Presented at 2010 American Transplant Congress  
4/28/2010 9:27:57 AM

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of eight clinical presentations related to kidney transplantation at the American Transplant Congress, being held May 1 – 5 in San Diego. Belatacept, which received a positive U.S. Food and Drug Administration (FDA) advisory committee vote on March 1 of this year, is currently under FDA review for the prophylaxis of organ rejection in adult kidney transplant recipients. In total, 17 abstracts from company-sponsored studies will be presented during the congress.
//-->